Former Merck & Co. New Vaccines Group leader Joseph Sullivan joins NTx to lead commercialization efforts following breakthrough year  

SANTA FE, N.M.–(BUSINESS WIRE)–Nature’s Toolbox (NTx), a biomanufacturing and bioinformatics company, today announced the appointment of Joseph Sullivan as Chief Commercial Officer to advance the go-to-market strategy for its novel biological manufacturing and development platform following a series of major milestones over the past year.

The company’s recent $13 million series A round led by Anzu Partners with participation from RA Capital Management, fueled continued platform development and the company has now brought Sullivan on board to commercialize its proprietary cell-free biosynthesis platform, which drastically reduces the cost and timeline for vaccine development.

Sullivan brings over 25 years of pharmaceutical and biotechnology experience to NTx. Over the course of his career, Sullivan has led the launch of two groundbreaking products, licensed new indications, and formed external collaborations to expand market access. During his tenure at Merck & Co Inc., he led the New Vaccines Product Group and managed the introduction of Gardasil® in the U.S., which garnered over $1 billion in revenue within its first year on the market. He also led the efforts to expand Singulair® into respiratory markets. Sullivan also co-founded Gypsy Basin Genomics, Inc., a biotechnology company accelerating the fight against HPV Cancers.

“What NTx has built is truly novel in the industry. I’m thrilled to be joining a team that is completely revolutionizing the manufacturing and production process for vaccines and biologics, especially during a time when the entire world’s attention is on the pharmaceutical industry,” Sullivan said. (Read more…) “The opportunity to bring this cell-free system for biological production to market and drive efficiency, sustainability and cost-savings, all while creating clean, quality treatments is a unique privilege, and I am looking forward to accelerating market adoption and additional growth.”

Sullivan will also serve on the NTx Board of Directors that was bolstered earlier this year by the high-profile additions of Andrew Weber, former U.S. Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense, and Charles McMillan, former director of the Los Alamos National Laboratory.

“As we near the end of a year marked by tremendous momentum, the addition of a seasoned industry expert like Joe will ensure that growth and technological innovation continues into 2021,” said Dr. Alexander Koglin, co-founder, NTx. “Joe’s invaluable experience launching two successful treatments into the market will bolster our business development and commercial strategy and eventually change the production process for biologicals on a widespread scale.”

For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx

Nature’s Toolbox, Inc. (NTx) is an early stage biomanufacturing and bioinformatics company based in Santa Fe, NM. The company has developed a proprietary host-independent biological manufacturing and development platform used for pharmaceutical drug discovery and manufacturing of biologicals to counter disease. For more information, please visit: https://www.ntxbio.com.

Contacts

Kalyn Schieffer

[email protected]

Former Merck & Co. New Vaccines Group leader Joseph Sullivan joins NTx to lead commercialization efforts following breakthrough year  

SANTA FE, N.M.–(BUSINESS WIRE)–Nature’s Toolbox (NTx), a biomanufacturing and bioinformatics company, today announced the appointment of Joseph Sullivan as Chief Commercial Officer to advance the go-to-market strategy for its novel biological manufacturing and development platform following a series of major milestones over the past year.

The company’s recent $13 million series A round led by Anzu Partners with participation from RA Capital Management, fueled continued platform development and the company has now brought Sullivan on board to commercialize its proprietary cell-free biosynthesis platform, which drastically reduces the cost and timeline for vaccine development.

Sullivan brings over 25 years of pharmaceutical and biotechnology experience to NTx. Over the course of his career, Sullivan has led the launch of two groundbreaking products, licensed new indications, and formed external collaborations to expand market access. During his tenure at Merck & Co Inc., he led the New Vaccines Product Group and managed the introduction of Gardasil® in the U.S., which garnered over $1 billion in revenue within its first year on the market. He also led the efforts to expand Singulair® into respiratory markets. Sullivan also co-founded Gypsy Basin Genomics, Inc., a biotechnology company accelerating the fight against HPV Cancers.

“What NTx has built is truly novel in the industry. I’m thrilled to be joining a team that is completely revolutionizing the manufacturing and production process for vaccines and biologics, especially during a time when the entire world’s attention is on the pharmaceutical industry,” Sullivan said. (Read more…) “The opportunity to bring this cell-free system for biological production to market and drive efficiency, sustainability and cost-savings, all while creating clean, quality treatments is a unique privilege, and I am looking forward to accelerating market adoption and additional growth.”

Sullivan will also serve on the NTx Board of Directors that was bolstered earlier this year by the high-profile additions of Andrew Weber, former U.S. Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense, and Charles McMillan, former director of the Los Alamos National Laboratory.

“As we near the end of a year marked by tremendous momentum, the addition of a seasoned industry expert like Joe will ensure that growth and technological innovation continues into 2021,” said Dr. Alexander Koglin, co-founder, NTx. “Joe’s invaluable experience launching two successful treatments into the market will bolster our business development and commercial strategy and eventually change the production process for biologicals on a widespread scale.”

For more information about NTx and its proprietary platform, please visit: https://www.ntxbio.com.

About NTx

Nature’s Toolbox, Inc. (NTx) is an early stage biomanufacturing and bioinformatics company based in Santa Fe, NM. The company has developed a proprietary host-independent biological manufacturing and development platform used for pharmaceutical drug discovery and manufacturing of biologicals to counter disease. For more information, please visit: https://www.ntxbio.com.

Contacts

Kalyn Schieffer

[email protected]